



Foscavir® (foscarnet) – First-time generic

- On February 3, 2021, Fresenius Kabi USA launched an [AP-rated](#) generic version of Clinigen's [Foscavir \(foscarnet\)](#) injection.
- Foscavir is approved for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome and acyclovir-resistant mucocutaneous herpes simplex virus infections in immunocompromised patients.
- Foscavir carries a boxed warning for renal impairment and seizures.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.